Medivir AB (LTS:0GP7) Ending Cash Position: kr253.50 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GP7 Medivir AB LTS:0GP7
44 GF Score
Price kr1.90
GF Value kr1.01
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Ending Cash Position?

Medivir AB LTS:0GP7 +10.54% 44 Ending Cash Position is kr253.50 Mil as of Jun. 2026. GuruFocus rates LTS:0GP7 with a GF Score™ of 44/100 and a GF Value™ of kr1.01 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Medivir AB's Ending Cash Position for the quarter that ended in Jun. 2026 was kr253.50 Mil.

Medivir AB's quarterly Ending Cash Position increased from Dec. 2025 (kr119.20 Mil) to Mar. 2026 (kr149.10 Mil) and increased from Mar. 2026 (kr149.10 Mil) to Jun. 2026 (kr253.50 Mil).

Medivir AB's annual Ending Cash Position declined from Dec. 2023 (kr169.52 Mil) to Dec. 2024 (kr62.53 Mil) but then increased from Dec. 2024 (kr62.53 Mil) to Dec. 2025 (kr119.21 Mil).

Medivir AB Ending Cash Position Related Terms

Medivir AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Medivir AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Ending Cash Position Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 221.17 117.43 169.52 62.53 119.21

Medivir AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.20 23.50 119.20 149.10 253.50
LTS:0GP7
44GF Score
Medivir AB LTS:0GP7
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Medivir AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=62.529+56.684
=119.21

Medivir AB's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=149.1+104.4
=253.50

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr253.50 Mil mean?
Medivir AB (LTS:0GP7) has a Ending Cash Position of kr253.50 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medivir AB and its competitors.
Is Medivir AB's Ending Cash Position too high?
Medivir AB's current Ending Cash Position is kr253.50 Mil. Overall, Medivir AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Ending Cash Position compare to VRTX and REGN?
Medivir AB's Ending Cash Position of kr253.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medivir AB and its competitors. Medivir AB's current Ending Cash Position is kr253.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.01, compared to a current price of kr1.90 — trading 88.2% above its estimated fair value. The current Ending Cash Position is kr253.50 Mil. Medivir AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current Ending Cash Position is kr253.50 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (LTS:0GP7) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.90 is trading 88.2% above its estimated GF Value™ of kr1.01. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for LTS:0GP7:

  • Ending Cash Position: kr253.50 Mil
  • GF Value™: kr1.01 vs. price of kr1.90 (88.2% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medivir AB Business Description

Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
44GF Score

Get the complete analysis for LTS:0GP7

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.90
Price
kr1.01
GF Value